Objective: To report the clinical and laboratory characteristics, as well as treatment and clinical outcomes of patients admitted for neurological diseases MESHD with and without COVID-19. Methods: In this retrospective, single center cohort study, we included all adult TRANS inpatients with confirmed COVID-19, admitted to a Neuro-COVID Unit from February 21, 2020, who had been discharged or died by April 5, 2020. Demographic, clinical, treatment, and laboratory data were extracted from medical records and compared (FDR-corrected) to those of neurological patients without COVID-19 admitted in the same period. Results: 173 patients were included in this study, of whom 56 were positive for COVID-19 while 117 were negative for COVID-19. Patients with COVID-19 were older, had a different distribution regarding admission diagnoses, including cerebrovascular disorders MESHD, and had a higher quick Sequential Organ Failure Assessment (qSOFA) score on admission (all p<0.05). In-hospital mortality rates and incident delirium MESHD delirium HP were significantly higher in the COVID-19 group (all p<0.005). COVID-19 and non-COVID patients with stroke MESHD stroke HP had similar baseline characteristics but patients with COVID-19 had higher modified Rankin scale scores at discharge, with a significantly lower number of patients with a good outcome (all p<0.001). In patients with COVID-19, multivariable regressions showed increasing odds of in-hospital death MESHD associated with higher qSOFA scores (odds ratio 4.47, 95% CI 1.21-16.5; p=0.025), lower platelet count (0.98, 0.97-0.99; p=0.005) and higher lactate dehydrogenase (1.01, 1.00-1.03; p=0.009) on admission. Conclusions: COVID-19 patients admitted with neurological disease MESHD, including stroke MESHD stroke HP, have a significantly higher in-hospital mortality, incident delirium MESHD delirium HP and higher disability than patients without COVID-19.